
%0 Journal Article
%A Butale, Bakani 
%A Woolley, Ian 
%A Cisera, Kathryn 
%A Korman, Tony 
%A Soldatos, Georgia 
%T <i>Corrigendum to</i>: Under-utilisation of cardioprotective glucose-lowering medication in diabetics living with HIV
%J Sexual Health
%D 2022/12/08
%V 19
%N 6
%P 583-583
%K 
%R https://doi.org/10.1071/SH22070_CO
%U https://www.publish.csiro.au/paper/SH22070_CO 
%X Diabetes is an increasingly common co-morbidity in people living with HIV (PLWH). Given new evidence demonstrating cardiovascular benefits of sodium glucose transporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP1RA) in diabetic patients, we reviewed medical charts of 262 PLWH at Monash Health through a 1-year retrospective cohort study to determine the rates of their use. Prevalence of diabetes was 13.4% (35) and 60% (21) had microvascular and macrovascular complications. Only 4% (95% CI 0.1%&#x2013;19.6%) of diabetic patients were receiving SGLT2i and 19% (95% CI 6%&#x2013;39.4%) were receiving GLP1RA. Prescribers should carefully consider their choice of glucose-lowering medication when treating PLWH. 
